HomeGUTS • NASDAQ
add
Fractyl Health Inc
Previous close
$1.01
Day range
$0.93 - $1.05
Year range
$0.83 - $3.72
Market cap
47.64M USD
Avg Volume
824.58K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 24.76M | 14.86% |
Net income | -23.74M | -614.48% |
Net profit margin | — | — |
Earnings per share | -0.49 | — |
EBITDA | -24.47M | -13.87% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 42.11M | -65.33% |
Total assets | 83.04M | -49.22% |
Total liabilities | 76.66M | -3.37% |
Total equity | 6.38M | — |
Shares outstanding | 48.98M | — |
Price to book | 7.77 | — |
Return on assets | -64.77% | — |
Return on capital | -77.99% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -23.74M | -614.48% |
Cash from operations | -25.08M | -114.15% |
Cash from investing | -448.00K | 57.70% |
Cash from financing | 171.00K | -99.83% |
Net change in cash | -25.36M | -128.74% |
Free cash flow | -15.87M | -84.12% |
About
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
Founded
2010
Headquarters
Website
Employees
109
